ibuprofen has been researched along with Nasal Catarrh in 5 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rhinogenic headache is frequently encountered in clinical practice." | 6.61 | Update on the pathophysiology and treatment of rhinogenic headache: focus on the ibuprofen/pseudoephedrine combination. ( Camaioni, A; Chiarugi, A, 2019) |
| " We sought to evaluate the effectiveness and safety of over the counter dosing of ibuprofen on pain and bleeding rates following ESS." | 5.56 | Effect of Over the Counter Ibuprofen Dosing after Sinus Surgery for Chronic Rhinosinusitis: A Prospective Cohort Pilot Study. ( Davis, GE; Humphreys, IM; Miller, C, 2020) |
| "Two studies were conducted to characterize multiple-dose pharmacokinetics and potential drug interactions of ibuprofen and pseudoephedrine combined in a suspension and to evaluate safety of this combination in children with common cold, flu, or sinusitis." | 3.76 | Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children. ( Gelotte, CK; Lavins, BJ; Pendley, C; Prior, MJ; Zimmerman, B, 2010) |
| "Rhinogenic headache is frequently encountered in clinical practice." | 2.61 | Update on the pathophysiology and treatment of rhinogenic headache: focus on the ibuprofen/pseudoephedrine combination. ( Camaioni, A; Chiarugi, A, 2019) |
| " We sought to evaluate the effectiveness and safety of over the counter dosing of ibuprofen on pain and bleeding rates following ESS." | 1.56 | Effect of Over the Counter Ibuprofen Dosing after Sinus Surgery for Chronic Rhinosinusitis: A Prospective Cohort Pilot Study. ( Davis, GE; Humphreys, IM; Miller, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, C | 1 |
| Humphreys, IM | 1 |
| Davis, GE | 1 |
| Ayoub, NF | 1 |
| Choby, G | 1 |
| Turner, JH | 1 |
| Abuzeid, WM | 1 |
| Raviv, JR | 1 |
| Thamboo, A | 1 |
| Ma, Y | 1 |
| Chandra, RK | 1 |
| Chowdhury, NI | 1 |
| Stokken, JK | 1 |
| O'Brien, EK | 1 |
| Shah, S | 1 |
| Akbar, N | 1 |
| Roozdar, P | 1 |
| Nayak, JV | 1 |
| Patel, ZM | 1 |
| Hwang, PH | 1 |
| Chiarugi, A | 1 |
| Camaioni, A | 1 |
| Gelotte, CK | 1 |
| Prior, MJ | 1 |
| Pendley, C | 1 |
| Zimmerman, B | 1 |
| Lavins, BJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-institutional, Randomized Controlled Trial Assessing Opioid Use and Analgesic Requirements After Endoscopic Sinus Surgery[NCT03783702] | Phase 4 | 118 participants (Actual) | Interventional | 2019-04-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 2.8 |
| Control Group | 2.9 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 2
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 2.5 |
| Control Group | 2.3 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 3
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.9 |
| Control Group | 2.1 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 4
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.5 |
| Control Group | 1.9 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 5
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.7 |
| Control Group | 1.6 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 6
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.5 |
| Control Group | 1.4 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: Average BPI score will be collected for postoperative day 7
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.3 |
| Control Group | 1.4 |
"The Brief Pain Inventory (BPI) Severity short form is a validated, patient-reported outcome measure that assesses pain over a 24-hour period. The Pain Severity score is calculated as a composite mean score using the degree of pain a patient experiences per day at its least, worst, average, and now. The score ranges from 0 to 10 (higher indicates more pain).~Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004. 20(5): 309-318." (NCT03783702)
Timeframe: BPI score will be collected at the preoperative visit
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 1.6 |
| Control Group | 1.0 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score was collected for postoperative day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 30.2 |
| Control Group | 29.4 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 2
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 27.0 |
| Control Group | 23.5 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 3
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 19.2 |
| Control Group | 22.5 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 4
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 14.1 |
| Control Group | 16.8 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 5
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 15.8 |
| Control Group | 15.0 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 6
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 13.9 |
| Control Group | 11.7 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for postoperative day 7
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 8.1 |
| Control Group | 10.1 |
"A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no pain with a score of 0 to worst imaginable pain, corresponding to a score of 100." (NCT03783702)
Timeframe: Average pain score will be collected for preoperative visit (the day before surgery)
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 12.4 |
| Control Group | 8.5 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected at the preoperative visit
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 0 |
| Control Group | 0 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 36.3 |
| Control Group | 38.9 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 2
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 23.0 |
| Control Group | 21.6 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 3
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 15.9 |
| Control Group | 12.9 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 4
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 9.3 |
| Control Group | 11.8 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 5
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 10.1 |
| Control Group | 7.8 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 6
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 6.5 |
| Control Group | 6.6 |
"A 10-cm visual analog scale (VAS) will be used to assess bleeding. The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from no bleeding with a score of 0 to continuous bleeding, corresponding to a score of 100." (NCT03783702)
Timeframe: Epistaxis severity will be collected for postoperative day 7
| Intervention | units on a scale (Mean) |
|---|---|
| Experimental Group | 4.6 |
| Control Group | 5.4 |
Patients kept a daily medication log and reported the number of doses consumed per day (650mg acetaminophen, 600mg ibuprofen, 5mg oxycodone). The mean number of medication doses per day was calculated for each treatment group. (NCT03783702)
Timeframe: Postoperative day 1 to 7
| Intervention | Average number of medication doses/day (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxycodone POD1 | Oxycodone POD2 | Oxycodone POD3 | Oxycodone POD4 | Oxycodone POD5 | Oxycodone POD6 | Oxycodone POD7 | Acetaminophen POD1 | Acetaminophen POD2 | Acetaminophen POD3 | Acetaminophen POD4 | Acetaminophen POD5 | Acetaminophen POD6 | Acetaminophen POD7 | Ibuprofen POD1 | Ibuprofen POD2 | Ibuprofen POD3 | Ibuprofen POD4 | Ibuprofen POD5 | Ibuprofen POD6 | Ibuprofen POD7 | |
| Control Group | 0.6 | 0.4 | 0.3 | 0.3 | 0.3 | 0.1 | 0 | 2.1 | 1.9 | 1.6 | 1.5 | 1.3 | 1.1 | 0.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Experimental Group | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 2.0 | 1.8 | 1.3 | 1.0 | 0.9 | 0.9 | 0.6 | 0.6 | 0.5 | 0.4 | 0.3 | 0.4 | 0.3 | 0.2 |
1 review available for ibuprofen and Nasal Catarrh
| Article | Year |
|---|---|
Update on the pathophysiology and treatment of rhinogenic headache: focus on the ibuprofen/pseudoephedrine combination.
Topics: Drug Administration Schedule; Drug Therapy, Combination; Headache; Humans; Ibuprofen; Placebo Effect | 2019 |
1 trial available for ibuprofen and Nasal Catarrh
| Article | Year |
|---|---|
Assessment of Opioid Use and Analgesic Requirements After Endoscopic Sinus Surgery: A Randomized Clinical Trial.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opi | 2021 |
3 other studies available for ibuprofen and Nasal Catarrh
| Article | Year |
|---|---|
Effect of Over the Counter Ibuprofen Dosing after Sinus Surgery for Chronic Rhinosinusitis: A Prospective Cohort Pilot Study.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Disease; Cohort St | 2020 |
Best drugs for what ails you: the brands to buy--and those to skip.
Topics: Acetaminophen; Anesthetics, Local; Cetirizine; Chlorpheniramine; Common Cold; Cough; Dextromethorpha | 2009 |
Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children.
Topics: Administration, Oral; Age Factors; Area Under Curve; Case-Control Studies; Child; Child, Preschool; | 2010 |